LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 188

Search options

  1. Article ; Online: Chez les sujets ayant eu un accident vasculaire cérébral ischémique mineur ou un accident ischémique transitoire à haut risque dans les 72heures, est-ce que la combinaison aspirine et clopidogrel donnée pour 21jours diminue la récidive d’AVC à 90jours comparativement à l’aspirine seule, tout en étant sécuritaire ?

    Lanthier, L / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2024  

    Title translation Among patients with mild ischemic stroke or high-risk TIA, does combined clopidogrel-aspirin therapy initiated within 72hours after stroke onset and given for 21 days reduce the recurrence of stroke at 90 days compared to aspirin alone, and is it safe?
    Language French
    Publishing date 2024-02-21
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2024.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Chez les sujets avec insuffisance rénale chronique modérée, diabétiques ou non, est-ce que l’empagliflozine entraîne un bénéfice rénal et cardiovasculaire comparativement au placebo, tout en étant sécuritaire ?

    Lanthier, L / Viau-Trudel, A / Plourde, M-E / Cauchon, M

    La Revue de medecine interne

    2023  Volume 44, Issue 6, Page(s) 319–320

    Title translation In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?
    MeSH term(s) Humans ; Kidney ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/epidemiology ; Benzhydryl Compounds/adverse effects ; Glucosides/adverse effects ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/drug therapy ; Hypoglycemic Agents/adverse effects
    Chemical Substances empagliflozin (HDC1R2M35U) ; Benzhydryl Compounds ; Glucosides ; Hypoglycemic Agents
    Language French
    Publishing date 2023-04-10
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2023.03.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée, est-ce que l’empagliflozine est efficace pour prévenir la mortalité cardiovasculaire et l’hospitalisation pour insuffisance cardiaque tout en étant sécuritaire ?

    Lanthier, L / Dussault, C / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2021  Volume 42, Issue 11, Page(s) 814–815

    Title translation For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?
    MeSH term(s) Cardiovascular System ; Heart Failure/drug therapy ; Hospitalization ; Humans ; Prognosis ; Stroke Volume ; Ventricular Function, Left
    Language French
    Publishing date 2021-10-30
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2021.10.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Chez les adultes admis aux soins intensifs avec pneumonie acquise en communauté grave, est-ce que l’ajout d’hydrocortisone au traitement standard diminue la mortalité à 28 jours, tout en étant sécuritaire, comparativement à un placebo ?

    Lanthier, L / Mayette, M / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2023  Volume 44, Issue 7, Page(s) 383–384

    Title translation In adults admitted to the intensive care unit for severe community-acquired pneumonia, does adding hydrocortisone to standard treatment reduce 28-days mortality compared to placebo, and is it safe?
    MeSH term(s) Humans ; Adult ; Hydrocortisone/therapeutic use ; Hospitalization ; Pneumonia/drug therapy ; Intensive Care Units ; Community-Acquired Infections/drug therapy
    Chemical Substances Hydrocortisone (WI4X0X7BPJ)
    Language French
    Publishing date 2023-05-12
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2023.04.442
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Chez le sujet sous ventilation mécanique depuis au moins 3jours, est-ce qu’un traitement d’amikacine inhalée donné pendant 3jours réduit l’incidence de pneumonie acquise sous ventilation mécanique et est sécuritaire comparativement au placebo ?

    Lanthier, L / Mayette, M / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2023  Volume 45, Issue 1, Page(s) 55–56

    Title translation In a patient undergoing mechanical ventilation for at least 3 days, does a 3-day course of inhaled amikacin reduce the incidence of ventilator-associated pneumonia compared to placebo, and is it safe?
    MeSH term(s) Humans ; Amikacin/therapeutic use ; Pneumonia, Ventilator-Associated/epidemiology ; Pneumonia, Ventilator-Associated/prevention & control ; Pneumonia, Ventilator-Associated/drug therapy ; Respiration, Artificial/adverse effects ; Incidence ; Anti-Bacterial Agents/therapeutic use ; Intensive Care Units
    Chemical Substances Amikacin (84319SGC3C) ; Anti-Bacterial Agents
    Language French
    Publishing date 2023-12-22
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2023.12.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Chez les sujets à risque élevé subissant une chirurgie non cardiaque, est-ce que l’acide tranexamique diminue le risque de saignement, tout en étant sécuritaire du point de vue cardiovasculaire, comparativement au placébo ?

    Lanthier, L / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2022  Volume 43, Issue 7, Page(s) 455–456

    Title translation In high-risk patients undergoing noncardiac surgery, does tranexamic acid result in a lower incidence of bleeding while being safe from a cardiovascular point of view compared to placebo?
    MeSH term(s) Antifibrinolytic Agents/adverse effects ; Cardiovascular System ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Hemorrhage/prevention & control ; Humans ; Incidence ; Tranexamic Acid/adverse effects
    Chemical Substances Antifibrinolytic Agents ; Tranexamic Acid (6T84R30KC1)
    Language French
    Publishing date 2022-06-17
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2022.05.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations.

    Pichon, Camille / Nachit, Maxime / Gillard, Justine / Vande Velde, Greetje / Lanthier, Nicolas / Leclercq, Isabelle A

    Frontiers in nutrition

    2022  Volume 9, Page(s) 1051157

    Abstract: Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world. Progression toward non-alcoholic steatohepatitis (NASH) is associated with alterations of skeletal muscle. One plausible ... ...

    Abstract Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world. Progression toward non-alcoholic steatohepatitis (NASH) is associated with alterations of skeletal muscle. One plausible mechanism for altered muscle compartment in liver disease is changes in ammonia metabolism. In the present study, we explored the hypothesis that NASH-associated hyperammonemia drives muscle changes as well as liver disease progression.
    Materials and methods: In
    Results: According to previous studies, 12 weeks of HFD induced NASH in all
    Conclusion: Our study confirms the perturbation of hepatic ammonia detoxification pathways in NASH. Results from the interventional experiments suggest a direct beneficial impact of LOLA on skeletal muscle during NASH development, though it does not improve ammonia metabolism or liver disease.
    Language English
    Publishing date 2022-11-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2776676-7
    ISSN 2296-861X
    ISSN 2296-861X
    DOI 10.3389/fnut.2022.1051157
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Chez les sujets avec diabète type 2 sous metformine, l’ajout de quelle classe d’antihyperglycémiant parmi une sulfonylurée (glimépiride), un inhibiteur du DPP-4 (sitagliptine), un agoniste des récepteurs du GLP-1 (liraglutide), ou de l’insuline glargine est le plus efficace pour attendre et maintenir une bonne maîtrise glycémique ?

    Lanthier, L / Mutchmore, A / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2022  Volume 44, Issue 1, Page(s) 48–49

    Title translation In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?
    MeSH term(s) Humans ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/pharmacology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Metformin/therapeutic use ; Metformin/pharmacology ; Sitagliptin Phosphate/therapeutic use ; Insulin Glargine/therapeutic use ; Liraglutide/therapeutic use ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Glucagon-Like Peptide 1/therapeutic use ; Glycemic Control ; Insulin/therapeutic use ; Blood Glucose ; Drug Therapy, Combination ; Treatment Outcome
    Chemical Substances Hypoglycemic Agents ; Metformin (9100L32L2N) ; Sitagliptin Phosphate (TS63EW8X6F) ; Insulin Glargine (2ZM8CX04RZ) ; glimepiride (6KY687524K) ; Liraglutide (839I73S42A) ; Dipeptidyl-Peptidase IV Inhibitors ; Glucagon-Like Peptide 1 (89750-14-1) ; Insulin ; Blood Glucose
    Language French
    Publishing date 2022-11-25
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2022.11.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Chez les sujets avec diabète type 2, insuffisance rénale chronique et albuminurie, est-ce que la finérénone, un antagoniste sélectif des récepteurs minéralocorticoïdes, est efficace et sécuritaire afin de ralentir la progression de l’IRC ?

    Lanthier, L / Plourde, M-É / Cauchon, M

    La Revue de medecine interne

    2021  Volume 42, Issue 2, Page(s) 144–145

    Title translation In patients with type 2 diabetes, chronic kidney disease and albuminuria, is finerenone, a selective minerocorticoid receptor antagonist, effective and safe for lowering CKD progression?
    MeSH term(s) Albuminuria/drug therapy ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Disease Progression ; Humans ; Naphthyridines ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy
    Chemical Substances Naphthyridines ; finerenone
    Language French
    Publishing date 2021-01-15
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2020.12.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Chez les femmes enceintes avec HTA préexistante légère, est-ce qu’une stratégie de traitement utilisant une cible de traitement<140/90mmHg comparativement à une surveillance sans traitement sauf si la TA>160/105mmHg réduit l’incidence de complications maternelles et périnatales tout en étant sécuritaire?

    Lanthier, Luc / Sauvé, Nadine / Plourde, Marc-Émile / Cauchon, Michel

    La Revue de medecine interne

    2022  Volume 43, Issue 8, Page(s) 514–515

    Title translation In pregnant women with mild chronic hypertension, does a treatment strategy using a treatment target<140/90mmHg compared to watchful waiting unless BP>160/105mmHg reduce the incidence of maternal and perinatal complications while being safe?
    MeSH term(s) Female ; Humans ; Pregnancy ; Hypertension/epidemiology ; Hypertension/therapy ; Incidence ; Infant Mortality ; Pregnant Women ; Watchful Waiting ; Infant, Newborn
    Language French
    Publishing date 2022-07-19
    Publishing country France
    Document type Letter
    ZDB-ID 604679-4
    ISSN 1768-3122 ; 0248-8663
    ISSN (online) 1768-3122
    ISSN 0248-8663
    DOI 10.1016/j.revmed.2022.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2451: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top